Last reviewed · How we verify
Generic acyclovir — Competitive Intelligence Brief
phase 3
Nucleoside analog antiviral
Viral DNA polymerase (HSV and VZV)
Infectious Disease / Virology
Small molecule
Live · refreshed every 30 min
Target snapshot
Generic acyclovir (Generic acyclovir) — University of Washington. Acyclovir inhibits viral DNA polymerase to prevent replication of herpes simplex virus and varicella-zoster virus.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Generic acyclovir TARGET | Generic acyclovir | University of Washington | phase 3 | Nucleoside analog antiviral | Viral DNA polymerase (HSV and VZV) | |
| Lonsurf | TIPIRACIL | Taiho Oncology Inc | marketed | Nucleoside Analog Antiviral [EPC] | Thymidine phosphorylase | 2015-01-01 |
| Dendrid | IDOXURIDINE | Novartis | marketed | Nucleoside Analog Antiviral | Thymidine kinase, cytosolic | 1963-01-01 |
| Peginterferon alfa-2a + ribavirin | Peginterferon alfa-2a + ribavirin | Hospital Clinico Universitario San Cecilio | marketed | Interferon alpha + nucleoside analog antiviral combination | Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase | |
| Valacyclovir (ZELITREX) | Valacyclovir (ZELITREX) | Assistance Publique - Hôpitaux de Paris | marketed | Nucleoside analog antiviral | Viral DNA polymerase (herpesvirus) | |
| VAL | VAL | Estetra | marketed | Nucleoside analog antiviral | Cytomegalovirus (CMV) DNA polymerase | |
| Acyclovir (ACV) | Acyclovir (ACV) | French National Agency for Research on AIDS and Viral Hepatitis | marketed | Nucleoside analog antiviral | Viral DNA polymerase (herpes simplex virus and varicella-zoster virus) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Lonsurf · RE46284 · US
- — Lonsurf · 10457666 · US
- — Lonsurf · 9527833 · US
- — Lonsurf · 9943537 · US
- — Lonsurf · 10456399 · US
- — Lonsurf · 10960004 · US
Sponsor landscape (Nucleoside analog antiviral class)
- Merck Sharp & Dohme LLC · 3 drugs in this class
- Hoffmann-La Roche · 2 drugs in this class
- Göteborg University · 2 drugs in this class
- Estetra · 1 drug in this class
- Padagis LLC · 1 drug in this class
- MinaPharm Pharmaceuticals · 1 drug in this class
- French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
- NYU Langone Health · 1 drug in this class
- Assistance Publique - Hôpitaux de Paris · 1 drug in this class
- Ain Shams University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Generic acyclovir CI watch — RSS
- Generic acyclovir CI watch — Atom
- Generic acyclovir CI watch — JSON
- Generic acyclovir alone — RSS
- Whole Nucleoside analog antiviral class — RSS
Cite this brief
Drug Landscape (2026). Generic acyclovir — Competitive Intelligence Brief. https://druglandscape.com/ci/generic-acyclovir. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab